CSL (OTCMKTS:CSLLY) Raised to “Strong-Buy” at The Goldman Sachs Group

CSL (OTCMKTS:CSLLY) was upgraded by The Goldman Sachs Group to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

CSL Trading Up 0.4 %

Shares of CSL stock opened at $86.16 on Thursday. The business’s fifty day simple moving average is $89.07 and its 200-day simple moving average is $96.47. CSL has a 52 week low of $83.31 and a 52 week high of $109.00. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.